CA
MACK

Crewe Advisors’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

Crewe Advisors’s Portfolio MACK Stock Details MACK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-127
Closed – – 281
2018
Q4 		$0 Hold
127
– – ﹤0.01% 239
2018
Q3 		$1K Hold
127
– – ﹤0.01% 232
2018
Q2 		$0 Hold
127
– – ﹤0.01% 294
2018
Q1 		$1K Hold
127
– – ﹤0.01% 269
2017
Q4 		$1K Buy
+127
New +$1.18K ﹤0.01% 266

Other funds holding MACK

NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
2L
22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
WSL
Western Standard LLC Los Angeles, California $190M AUM 40.88% 1-Year Est. Return
TCIM
TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WIM
Wittenberg Investment Management Carlisle, Massachusetts $269M AUM 28.17% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Crewe Advisors's MACK Position: Q1 2019 in Review

Crewe Advisors sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q1 2019, closing a stake of 127 shares.

Crewe Advisors first reported a position in MACK in Q4 2017 and held it in 5 quarters. The position peaked at $1K in Q3 2018. 54 funds tracked by Wall St. Rank hold MACK as of Q1 2019.

  • Crewe Advisors reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q1 2019 after selling out during the quarter.
  • Crewe Advisors sold 127 Merrimack Pharmaceuticals, Inc. shares in Q1 2019.
  • Crewe Advisors first reported a position in Merrimack Pharmaceuticals, Inc. in Q4 2017 and held it in 5 quarters.
  • Crewe Advisors's Merrimack Pharmaceuticals, Inc. position peaked at $1K in Q3 2018.
  • 54 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q1 2019.

Based on Crewe Advisors's 13F filing for Q1 2019, filed 10 May 2019.